Polysensitization Across 86,416 European Patch-Test Patients

November 11, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: How much did polysensitization vary across 11 countries, and what might referral patterns explain?

Study snapshot

Study element	Reported detail
Population	86,416 consecutively patch-tested patients from 57 departments in 11 European countries.
Design	Retrospective European Surveillance System on Contact Allergies analysis of baseline-series results.
Comparator	Prevalence and reaction intensity were compared across countries, regions and patient factors including occupational dermatitis.
Timepoint	January 2009 through December 2014.
Key result	Standardized polysensitization prevalence was 7.02%, ranging from 12.7% in Austria to 4.6% in Italy. Female sex, occupational dermatitis and age over 40 were reported risk factors.
Funding/conflict context	The indexed abstract does not state funding or conflicts and does not evaluate a moisturizer.

What was actually measured?

Standardized polysensitization prevalence was 7.02%, ranging from 12.7% in Austria to 4.6% in Italy. Female sex, occupational dermatitis and age over 40 were reported risk factors.

Cross-country variation likely reflects case mix and referral practice as well as exposure, which the authors explicitly noted.

The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.

What the result does not prove

Patch-test referral data are not population prevalence; departments differed in patients and practice, and retrospective associations cannot identify individual causes.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.

Exposure detail matters more than the job label

Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve on days away or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredient information and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes